Targeting angiogenesis in melanoma

References

• Garbe C, Leiter U. Melanoma epidemiology and trends. Clin. Dermatol.27(1), 3–9 (2009).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and Worldwide. Skin Pharmacol. Appl. Skin Physiol.14(5), 280–290 (2001).
   PubMedGoogle Scholar
• Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol.19(16), 3622–3634 (2001).
   PubMed Web of Science ®Google Scholar
• Ahmed I. Malignant melanoma: prognostic indicators. Mayo Clin. Proc.72(4), 356–361(1997).
   PubMed Web of Science ®Google Scholar
• Garbe C, Buttner P, Bertz J et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer75(10), 2484–2491 (1995).
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol.19(16), 3635–3648 (2001).
   PubMed Web of Science ®Google Scholar
• Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res.10(1), 81–92 (2000).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol.18(1), 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Bedikian A, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol.24(29), 4738–4745 (2006).
   PubMed Web of Science ®Google Scholar
• Ribas A, Hauschild A, Kefford R, Gomez-Navarro J, Pavlov D, Marshall MA. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol.26(15 Suppl.), LBA9011 (2008).
   Google Scholar
• Patel PM, Suciu S, Mortier L et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomized Phase III study (EORTC 18032). Ann. Oncol.19(Suppl. 8), LBA8 (2008).
   Google Scholar
• Eigentler T, Caroli U, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol.4(12), 748–759 (2003).
   PubMed Web of Science ®Google Scholar
• Ives N, Stowe R, Lorigan P, Wheatley K. Meta-analysis of chemotherapy and biochemotherapy in metastatic malignant melanoma. J. Clin. Oncol.25(34), 3426–3434 (2007).
   Google Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Weber JS, Berman D, Siegel J et al. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J. Clin. Oncol.26(15 Suppl.) (2008) (Abstract 9010).
   Web of Science ®Google Scholar
• Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, Phase III trial of bacillus Calmette–Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8508).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol.26(32), 5233–5239 (2008).
   PubMed Web of Science ®Google Scholar
• Kasper B, D’Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: a new beginning? Crit. Rev. Oncol. Hematol.62(1), 16–22 (2007).
   PubMed Web of Science ®Google Scholar
• Queirolo P, Acquati M. Targeted therapies in melanoma. Cancer Treat. Rev.32(7), 524–531 (2006).
   PubMed Web of Science ®Google Scholar
• Lorigan P, Eisen T, Hauschild A. Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future? Exp. Dermatol.17(5), 383–394 (2008).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285(21), 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Srivastava A, Ralhan R, Kaur J. Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc. Res. Tech.60(2), 208–224 (2003).
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature438(7070), 932–936 (2005).
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82(1), 4–6 (1990).
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med.333(26), 1757–1763 (1995).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev.25(4), 581–611 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature407(6801), 249–257 (2000).
   PubMed Web of Science ®Google Scholar
• Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci.28(9), 488–494 (2003).
   PubMed Web of Science ®Google Scholar
• Kaplan R. N. et al. VEGFR1-positive hematopoietic bone marrow progenitors initiate the premestatic niche. Nature438, 820–827 (2005).
   PubMed Web of Science ®Google Scholar
• Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesisand lymphangiogenesis. Exp. Cell Res.312(5), 549–560 (2006).
   PubMed Web of Science ®Google Scholar
• Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer2(11), 826–835 (2002).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Karamysheva AF. Mechanisms of angiogenesis. Biochemistry (Mosc.)73(7), 751–762 (2008).
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med.12(1), 13–19 (2002).
   PubMed Web of Science ®Google Scholar
• Ciotti P, Rainero ML, NicoloG et al. Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Res.5(1), 41–47 (1995).
   PubMed Web of Science ®Google Scholar
• Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int. J. Cancer56(6), 853–857 (1994).
   PubMed Web of Science ®Google Scholar
• Westphal JR,Van’t Hullenaar R, Peek R, et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo.Int. J. Cancer.86(6), 768–776 (2000).
   PubMed Web of Science ®Google Scholar
• Rodeck U, Melber K, Kath R et al. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J. Invest. Dermatol.97(1), 20–26 (1991).
   PubMed Web of Science ®Google Scholar
• Graeven U, Fiedler W, Karpinski S et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J. Cancer Res. Clin. Oncol.125(11), 621–629 (1999).
   PubMed Web of Science ®Google Scholar
• Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine12(6), 547–554 (2000).
   PubMed Web of Science ®Google Scholar
• Erhard H, Rietveld FJ, van Altena MC, Bröcker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res.7(Suppl. 2), S19–S26 (1997).
   Web of Science ®Google Scholar
• Marcoval J, Moreno A, Graells J et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J. Cutan. Pathol.24(4), 212–218 (1997).
   PubMed Web of Science ®Google Scholar
• Brychtova S, Bezdekova M, Brychta T, Tichy M. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma55(4), 273–279 (2008).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rappl G, Tilgen W et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol.19(2), 577–583 (2001).
   PubMed Web of Science ®Google Scholar
• Mouawad R, Soubrane C, Khayat D. Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A,C,D) and their receptors (R1, R2, and R3) in advanced melanoma patients. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8540).
   Google Scholar
• Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer76(7), 930–934 (1997).
   PubMed Web of Science ®Google Scholar
• Lacal PM, Failla CM, Pagani E et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J. Invest. Dermatol.115(6), 1000–1007 (2000).
   PubMed Web of Science ®Google Scholar
• Liu B, Earl HM, Baban D et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem. Biophys. Res. Commun.217(3), 721–727 (1995).
   PubMed Web of Science ®Google Scholar
• Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev.24(2), 195–222 (2005).
   PubMed Web of Science ®Google Scholar
• Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer8(8), 604–617 (2008).
   PubMed Web of Science ®Google Scholar
• Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer8(8), 618–631 (2008).
   PubMed Web of Science ®Google Scholar
• Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev.27(1), 31–40 (2008).
   PubMed Web of Science ®Google Scholar
• Schmid MC, Varner JA. Myeloid cell trafficking and tumor angiogenesis. Cancer Lett.250(1), 1–8 (2007).
   PubMed Web of Science ®Google Scholar
• McLean K, Buckanovich RJ. Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Transl. Res.151(2), 59–67 (2008).
   PubMed Web of Science ®Google Scholar
• Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res.68(14), 5501–5504 (2008).
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev.25(3), 315–322 (2006).
   PubMed Web of Science ®Google Scholar
• Dirkx AE, Oude Egbrink MG et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res.63(9), 2322–2329 (2003).
   PubMed Web of Science ®Google Scholar
• Varney ML, Olsen KJ, Mosley RL, Singh RK. Paracrine regulation of vascular endothelial growth factor-A expression during macrophage–melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J. Interferon Cytokine Res.25(11), 674–683 (2005).
   PubMed Web of Science ®Google Scholar
• Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J. Immunol.166(11), 6483–6490 (2001).
   PubMed Web of Science ®Google Scholar
• Gazzaniga S, Bravo AI, Guglielmotti A et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol.127(8), 2031–2041 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun.333(2), 328–335 (2005).
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Varker A, Biber J, Kefauver C et al. A randomized Phase 2 trial of bevacizumab with or without daily low-dose interferon α-2b in metastatic malignant melanoma. Ann. Surg. Oncol.14(8), 2367–2376 (2007).
   PubMed Web of Science ®Google Scholar
• Vihinen P, Hernberg M, Vuoristo M, Tyynela K, Laukka M, Pyrhonen S. A Phase II trial of bevacizumab (bev) with dacarbazine (DTIC) and daily low-dose interferon-α-2a (IFN-α-2a) as frst line treatment in metastatic melanoma. Program of Perspectives in Melanoma XII. Scheveningen/The Hague, The Netherlands, 2–4 October 2008 (Poster Abstract P-009).
   Google Scholar
• Wyman K, Spigel D, Puzanov I et al. A multicenter Phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8539).
   Google Scholar
• Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer115(1), 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• Boasberg P, Hamid O, O’Day S, Weber R, Splitler L. Nab-paclitaxel and bevacizumab as first-line therapy in patients with stage IV melanoma. Program of Perspectives in Melanoma XII. Scheveningen/The Hague, The Netherlands, 2–4 October 2008 (Oral Abstract O-004).
   Google Scholar
• González-Cao M, Viteri S, Díaz-Lagares A et al. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology74(1–2), 12–16 (2008).
   PubMed Web of Science ®Google Scholar
• Dupont J, Schwartz LH, Koutcher J et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies J. Clin. Oncol.22(14 Suppl.) (2004) (Abstract 3009).
   Google Scholar
• Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF Trap in a Phase I clinical trial of patients with advanced solid tumors. J. Clin. Oncol.23(16 Suppl.) (2005) (Abstract 3029).
   PubMed Web of Science ®Google Scholar
• Hilger RA, Scheulen ME, Strumberg D. The Ras–Raf–MEK–ERK pathway in the treatment of cancer. Onkologie25(6), 511–518 (2002).
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res.62(23), 6997–7000 (2002).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64(19), 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer95(5), 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Brose M, Schucter L et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J. Clin. Oncol.22(14 Suppl.) (2004) (Abstract 7507).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Schiller J, Schuchter LM et al. A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res.14(15), 4836–4842 (2008).
   PubMed Web of Science ®Google Scholar
• Agarwala S, Keilholz U, Hogg D et al. Randomised Phase III trial of paclitaxel + carboplatin with or without sorafenib in patients with advanced melanoma. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8510).
   PubMed Web of Science ®Google Scholar
• Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol. Cancer Ther.2(8), 753–763 (2003).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Gore ME et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J. Clin. Oncol.23(16 Suppl.) (2005) (Abstract 7508).
   Google Scholar
• Eisen T, Marais R, Affolter A et al. An open-label Phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8529).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol.26(13), 2178–2185 (2008).
   PubMed Web of Science ®Google Scholar
• Amaravadi R, Schuchter L, McDermott D et al. Updated results of a randomized Phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 85270).
   Google Scholar
• Fruehauf JP, Lutzky J, McDermott DF. Axitinib (AG-013736) in patients with metastatic melanoma: a Phase II study. J. Clin. Oncol.26(15 Suppl.) (2008) (Abstract 9006).
   Web of Science ®Google Scholar
• Rini BI, Schiller JH, Fruehauf JP et al. Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). J. Clin. Oncol.26(15S) (2008) (Abstract 3543).
   Google Scholar
• Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin. Cancer Res.10(12 Pt 1), 4048–4054 (2004).
   PubMed Web of Science ®Google Scholar
• Mita MM, Rowinsky EK, Forero L et al. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother. Pharmacol.59(2), 165–174 (2007).
   PubMed Web of Science ®Google Scholar
• Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs9(12), 1324–1335 (2008).
   PubMed Web of Science ®Google Scholar
• Renhowe PA, Pecchi S, Shafer CM et al. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J. Med. Chem.52(2), 278–292 (2009).
   PubMed Web of Science ®Google Scholar
• Kim K, Diwan A, Papadopoulos A et al. A randomised Phase II study of EMD 121974 in patients with metastatic melanoma. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8548).
   Google Scholar
• Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.24(3), 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Bamias A, Dimopoulos MA. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert. Opin. Invest. Drugs14(1), 45–55 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang S, Li M, Gu Y et al. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J. Exp. Clin. Cancer Res.27, 60 (2008).
   PubMed Web of Science ®Google Scholar
• Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem.276(25), 22382–22387 (2001).
   PubMed Web of Science ®Google Scholar
• Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogous have distinct and opposing effects on TNF-α and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Immunol.130, 75–84 (2002).
   PubMed Web of Science ®Google Scholar
• Eisen T, Boshoff C, Mak I et al. Continuous low dose thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer82(4), 812–817 (2000).
   PubMed Web of Science ®Google Scholar
• Reiriz AB, Richter MF, Fernandes S et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res.14(6), 527–531 (2004).
   PubMed Web of Science ®Google Scholar
• Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res.14(1), 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Danson S, Lorigan P, Arance A et al. A randomised study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). J. Clin. Oncol.21(13), 2551–2557 (2003).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol.21(17), 3351–3356 (2003).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Lis E, Menell JH et al. Temozoomide plus thalidomide in patients with brain metastases from melanoma: a Phase II study. Cancer103(12), 2590–2597 (2005).
   PubMed Web of Science ®Google Scholar
• Krown SE, Niedzwiecki D, Hwu WJ et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer.107(8), 1883–1890 (2006).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Sosman JA, Agarwala S et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a Phase II Cytokine Working Group study. Cancer113(8), 2139–2145 (2008).
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Moon J, Clark JI et al. Evaluation of interferon α-2B and thalidomide in patients with disseminated malignant melanoma, Phase 2, SWOG 0026. Cancer110(10), 2269–2275 (2007).
   PubMed Web of Science ®Google Scholar
• Clark J, Moon J, Hutchins LF et al. Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508. J. Clin. Oncol.26(15S) (2008) (Abstract 9007).
   Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer4(4), 314–322 (2004).
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Michael A, Clarke IA et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer90(5), 955–961 (2004).
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br. J. Cancer93(6), 613–619 (2005).
   PubMed Web of Science ®Google Scholar
• Bedikian A, Kim K, Papadopoulos N et al. Preliminary results from a Phase II study of the combination of lenalidomide and DTIC in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8533).
   Google Scholar
• Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin avh3 antagonism. Anti-Cancer Agents Med. Chem.6(5), 407–428 (2006).
   PubMedGoogle Scholar
• Hersey P, Sosman J, O’Day S et al. A Phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human a v b 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J. Clin. Oncol.23(16 Suppl.) (2005) (Abstract 7507).
   Google Scholar
• Mullamitha S, Ton C, Parker G et al. Phase I evaluation of a fully human anti-av integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumours. Clin. Cancer Res.13(7), 2128–2135 (2007).
   PubMed Web of Science ®Google Scholar
• O’Day S, Pavlick A, Loquai C et al. Phase 2 study of the safety and efficacy of the human monoclonal antibody CNTO 95 alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: interim results. Program of Perspectives in Melanoma XII. Scheveningen/The Hague, The Netherlands, 2–4 October 2008. (Poster Abstract P-064).
   Google Scholar
• Kim S, Bell K, Mousa SA,Varner JA. Regulation of angiogenesis in vivo by ligation of integrin a5h1 with the central cell-binding domain of fibronectin. Am. J. Pathol.156(4), 1345–1362 (2000).
   PubMed Web of Science ®Google Scholar
• Qian F, Zhang ZC,Wu XF, Li YP, Xu Q. Interaction between integrin a(5) and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem. Biophys. Res. Commun.333(4), 1269–1275 (2005).
   PubMed Web of Science ®Google Scholar
• Cranmer L, Bedikian AY, Ribas A et al. Phase II study of volociximab (M200), an a5b1 anti-integrin antibody in metastatic melanoma. J. Clin. Oncol.24(18 Suppl.) (2006) (Abstract 8011).
   Google Scholar
• Barton J. A multicenter Phase II study of volociximab in patients with relapsed metastatic melanoma. J. Clin. Oncol.26(15 Suppl.) (2008) (Abstract 9051).
   Google Scholar
• Kim KB, Diwan AH, Papadopoulos NE et al. A randomized Phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM). J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8548).
   Google Scholar
• Tentori L, Dorio AS, Muzi A et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol. Rep.19(4), 1039–1043 (2008).
   PubMed Web of Science ®Google Scholar
• Wheatley K, Ives N, Eggermont A et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 8526).
   Google Scholar
• Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK. Design and conduct of Phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur. J. Cancer.44(1), 25–29 (2008).
   PubMed Web of Science ®Google Scholar
• Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and other considerations in Phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur. J. Cancer.44(1), 19–24 (2008).
   PubMed Web of Science ®Google Scholar
• Kummar S, Doroshow JH, Tomaszewski JE, Hilary Calvert A, Lobbezoo M, Giaccone G; on behalf of the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Phase 0 clinical trials: recommendations from the task force on methodology for the development of innovative cancer therapies. Eur. J. Cancer.45(5), 741–746 (2009).
   PubMed Web of Science ®Google Scholar
• Bedikian A, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol.24(29), 4738–4745 (2006).
   PubMed Web of Science ®Google Scholar
• Sessa C, Guibal A, Del Conte G, Rüegg C. Biomarkers of angiogenesis for the development of anti-angiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol.5(7), 378–391 (2008).
   PubMedGoogle Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer8(8), 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updat.11(6), 219–230 (2008).
   PubMed Web of Science ®Google Scholar
• Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol.26(17), 2839–2845 (2008).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res.14(20), 6371–6375 (2008).
   PubMed Web of Science ®Google Scholar
• Sosman JA, Flaherty KT, Atkins MB et al. Updated results of Phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J. Clin. Oncol.26(15 Suppl.) (2008) (Abstract 5011).
   Google Scholar